DAYBUE® (trofinetide)
Rett Syndrome
Approved/CommercialMarketed
Key Facts
About Acadia Pharmaceuticals
Acadia Pharmaceuticals is dedicated to advancing care for patients with neurological disorders and rare diseases who have few or no treatment options. The company has successfully brought two FDA-approved therapies to market: NUPLAZID® (pimavanserin) for Parkinson's disease psychosis and DAYBUE® (trofinetide) for Rett syndrome. Acadia maintains a clinical pipeline focused on expanding indications for its core assets and developing novel treatments for conditions like Alzheimer's disease psychosis. The company operates with a patient-centric approach, targeting complex care areas where significant unmet medical needs exist.
View full company profileTherapeutic Areas
Other Rett Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| TSHA-102 | Taysha Gene Therapies | Phase 1/2 |
| Trofinetide (NNZ-2566) / DAYBUE™ | Neuren Pharmaceuticals | Approved |
| ANAVEX®2-73 (blarcamesine) | Anavex Life Sciences | Phase 2/3 |
| NGN-401 | Neurogene | Phase 1/2 |